Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)

DOI Web Site Web Site PubMed 4 Citations 37 References
  • Ohoka Nobumichi
    Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences
  • Ujikawa Osamu
    Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.
  • Shimokawa Kenichiro
    Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.
  • Sameshima Tomoya
    Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.
  • Shibata Norihito
    Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences
  • Hattori Takayuki
    Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences
  • Nara Hiroshi
    Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.
  • Cho Nobuo
    Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.
  • Naito Mikihiko
    Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences

Search this article

Abstract

<p>Targeted protein degradation by small molecules is an emerging modality with significant potential for drug discovery. We previously developed chimeric molecules, termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs), which induce the ubiquitylation and proteasomal degradation of target proteins. This degradation is mediated by the IAPs; the target proteins include bromodomain-containing protein 4 (BRD4), an epigenetic regulator protein. The SNIPER that degrades this particular protein, SNIPER(BRD)-1, consists of an IAP antagonist LCL-161 derivative and a bromodomain and extra-terminal (BET) inhibitor, (+)-JQ-1. SNIPER(BRD)-1 also degrades a cellular inhibitor of apoptosis protein 1 (cIAP1) and an X-linked inhibitor of apoptosis protein (XIAP), the mechanisms of which are not well understood. Here, we show that the degradation of cIAP1 and XIAP by SNIPER(BRD)-1 is induced via different mechanisms. Using a chemical biology-based approach, we developed two inactive SNIPERs, SNIPER(BRD)-3 and SNIPER(BRD)-4, incapable of degrading BRD4. SNIPER(BRD)-3 contained an N-methylated LCL-161 derivative as the IAP ligand, which prevented it from binding IAPs, and resulted in the abrogated degradation of cIAP1, XIAP, and BRD4. SNIPER(BRD)-4, however, incorporated the enantiomer (−)-JQ-1 which was incapable of binding BRD4; this SNIPER degraded cIAP1 but lost the ability to degrade XIAP and BRD4. Furthermore, a mixture of the ligands, (+)-JQ-1 and LCL-161, induced the degradation of cIAP1, but not XIAP and BRD4. These results indicate that cIAP1 degradation is triggered by the binding of the IAP antagonist module to induce autoubiquitylation of cIAP1, whereas a ternary complex formation is required for the SNIPER-induced degradation of XIAP and BRD4.</p>

Journal

Citations (4)*help

See more

References(37)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top